Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.7 ILa | -0.60% | 0.00% | -56.28% |
Sales 2024 * | 14.36M 5.47B | Sales 2025 * | 27.77M 10.57B | Capitalization | 52.63M 20.04B |
---|---|---|---|---|---|
Net income 2024 * | -47M -17.89B | Net income 2025 * | -36M -13.71B | EV / Sales 2024 * | 3.66 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.9 x |
P/E ratio 2024 * |
-2.19
x | P/E ratio 2025 * |
-
| Employees | 79 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.64% |
Latest transcript on BioLineRx Ltd.
1 day | -0.60% | ||
Current month | -40.57% | ||
1 month | -43.00% | ||
3 months | -47.81% | ||
6 months | -53.61% | ||
Current year | -56.28% |
Managers | Title | Age | Since |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 62 | 09-05-23 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 08-12-31 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 17-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 14-02-23 |
Avraham Molcho
BRD | Director/Board Member | 66 | 09-12-31 |
Aharon Schwartz
CHM | Chairman | 80 | 03-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 16.7 | -0.60% | 1,041,027 |
24-04-24 | 16.8 | -1.18% | 491,903 |
24-04-21 | 17 | +1.80% | 678,535 |
24-04-18 | 16.7 | -2.34% | 1,098,013 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 25, 2024 at 07:24 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.28% | 52.51M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- BLRX Stock